Logo

Coherus and Junshi Present Interim Results of Toripalimab in P-III CHOICE-01 Trial as 1L Treatment for Non-Small Cell Lung Cancer at WCLC 2021

Share this

Coherus and Junshi Present Interim Results of Toripalimab in P-III CHOICE-01 Trial as 1L Treatment for Non-Small Cell Lung Cancer at WCLC 2021

Shots:

  • The P-III CHOICE-01 trial evaluates toripalimab + CT vs CT alone in 465 patients in a ratio (2:1) with advanced sq./nonsq. NSCLC without driver mutations
  • The interim analysis met its 1EPs i.e.- improvement in PFS- superior ORR & DoR- OS data are still maturing. The safety profile was consistent with PD-1 inhibitor while final PFS & additional interim OS analyses are expected in later 2021
  • The companies plan to discuss with US FDA for submission of toripalimab’s BLA to treat NSCLC. The therapy has received FTD for mucosal melanoma- ODD for NPC- mucosal melanoma & soft tissue sarcoma- BTD for combination therapy as 1L treatment & for monothx. as 2L treatment of recurrent or metastatic NPC

  | Ref: Globe Newswire | Image: Coherus

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions